Aquestive Therapeutics (NASDAQ:AQST) Earns Buy Rating from HC Wainwright

Aquestive Therapeutics (NASDAQ:AQST)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a research report issued on Wednesday,Benzinga reports. They currently have a $10.00 target price on the stock. HC Wainwright’s price target suggests a potential upside of 249.65% from the company’s current price.

AQST has been the subject of several other research reports. Raymond James set a $7.00 price objective on Aquestive Therapeutics in a research report on Friday, March 7th. Alliance Global Partners reiterated a “buy” rating on shares of Aquestive Therapeutics in a report on Friday, March 7th. Cantor Fitzgerald started coverage on shares of Aquestive Therapeutics in a report on Tuesday, December 17th. They set an “overweight” rating and a $17.00 price objective on the stock. Finally, Lake Street Capital dropped their target price on shares of Aquestive Therapeutics from $10.00 to $8.00 and set a “buy” rating for the company in a report on Friday, March 7th. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Aquestive Therapeutics currently has a consensus rating of “Buy” and an average target price of $10.57.

Aquestive Therapeutics Stock Performance

AQST stock opened at $2.86 on Wednesday. The stock has a market capitalization of $282.77 million, a PE ratio of -6.36 and a beta of 2.76. The company has a fifty day moving average of $2.98 and a 200-day moving average of $3.91. Aquestive Therapeutics has a one year low of $2.24 and a one year high of $5.80.

Aquestive Therapeutics (NASDAQ:AQST) last announced its quarterly earnings data on Wednesday, March 5th. The company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.05). The business had revenue of $11.87 million during the quarter, compared to the consensus estimate of $13.11 million. Equities analysts forecast that Aquestive Therapeutics will post -0.46 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Aquestive Therapeutics

Large investors have recently bought and sold shares of the stock. Verition Fund Management LLC purchased a new stake in shares of Aquestive Therapeutics in the third quarter valued at $995,000. State Street Corp grew its stake in Aquestive Therapeutics by 52.1% in the 3rd quarter. State Street Corp now owns 1,496,739 shares of the company’s stock worth $7,454,000 after acquiring an additional 512,682 shares during the period. Harvey Capital Management Inc. grew its stake in Aquestive Therapeutics by 1,419.3% in the 4th quarter. Harvey Capital Management Inc. now owns 267,390 shares of the company’s stock worth $952,000 after acquiring an additional 249,790 shares during the period. Wellington Management Group LLP acquired a new position in Aquestive Therapeutics in the 3rd quarter valued at $922,000. Finally, BNP Paribas Financial Markets lifted its stake in shares of Aquestive Therapeutics by 252.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 18,826 shares of the company’s stock worth $94,000 after purchasing an additional 13,481 shares during the period. Institutional investors and hedge funds own 32.45% of the company’s stock.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.